[304] PTM BIOSCIENCES IS PROMOTING PRECISION MEDICINE BY TRANSFORMING POST-TRANSLATIONAL MODIFICATIONS INTO NOVEL THERAPEUTIC TARGETS AND BIOMARKERS FOR DISEASE MANAGEMENT

Baruch Schori, CEO, PTM Biosciences, Israel

Investment Rational

Current medical practice is suboptimal, especially in oncology where the overall percentage of responders to even the newest drugs is <50%. PTM Biosciences is dedicated to advancing precision medicine, by gaining functional insights and transforming Post-Translational Modifications into novel therapeutic targets and biomarkers for disease management. Market opportunities are significant as our technology addresses numerous unmet needs in lucrative markets.

Business Strategy

PTM Biosciences utilizes its technology for precision medicine applications:

- PTM-based predictive/prognostic kits for disease management will be sold to health providers (HMOs, medical centers) as stand-alone products for point-of-care utilization and generate near-term revenues.
- Drug development - several potential novel targets identified will be further validated and developed with strategic collaborators such as Pharmaceutical companies, and will generate long-term revenues.

Core Technology

PTM Biosciences is developing and commercializing a proprietary technology conceived at the Harvard University by Yifat Merbl, PhD, facilitating high throughput analysis of protein modifications. Analyzing liquid biopsies and tissues of diverse clinical conditions, we generate patient-specific, activity-based signatures, fundamental for understanding the molecular basis of the disease and serving as a source for novel therapeutic targets and predictive biomarkers.

Product Profile/Pipeline

Supported by clinical luminaries and key opinion leaders, we collaborate with leading medical centers and research institutions conducting innovative research and seminal clinical studies to address unmet clinical needs in oncology and autoimmune diseases. Pipeline includes a kit to predict sensitivity to proteasome inhibitors in Multiple Myeloma; a kit to predict sensitivity to immunotherapy in Melanoma; and a kit to assess disease activity and flares in Lupus.

What’s Next?

Based on our technology and gained experience, multiple kits in various clinical indications will be further developed and commercialized as point-of-care predictive/prognostic kits allowing, in a fast and accessible way, the optimization of therapy route, thus facilitating precision medicine, improving the clinical outcome, and reducing healthcare expenditures. The company is seeking strategic partners to support its clinical activities, commercialization initiatives and growth.